U.S. markets closed
  • S&P 500

    3,443.12
    +16.20 (+0.47%)
     
  • Dow 30

    28,308.79
    +113.37 (+0.40%)
     
  • Nasdaq

    11,516.49
    +37.61 (+0.33%)
     
  • Russell 2000

    1,617.71
    +4.08 (+0.25%)
     
  • Crude Oil

    41.51
    +0.05 (+0.12%)
     
  • Gold

    1,915.10
    -0.30 (-0.02%)
     
  • Silver

    24.96
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1834
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • GBP/USD

    1.2956
    +0.0009 (+0.07%)
     
  • USD/JPY

    105.4900
    +0.0200 (+0.02%)
     
  • BTC-USD

    11,927.86
    +870.85 (+7.88%)
     
  • CMC Crypto 200

    239.54
    +0.62 (+0.26%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

CLASS ACTION UPDATE for POR, FENC and ODT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·3 mins read

NEW YORK, NY / ACCESSWIRE / September 18, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

POR Shareholders Click Here: https://www.zlk.com/pslra-1/portland-general-electric-company-information-request-form?prid=9397&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-information-request-form?prid=9397&wire=1
ODT Shareholders Click Here: https://www.zlk.com/pslra-1/odonate-therapeutics-inc-information-request-form?prid=9397&wire=1

* ADDITIONAL INFORMATION BELOW *

Portland General Electric Company (NYSE:POR)

POR Lawsuit on behalf of: investors who purchased April 24, 2020 - August 24, 2020
Lead Plaintiff Deadline : November 2, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/portland-general-electric-company-information-request-form?prid=9397&wire=1

According to the filed complaint, during the class period, Portland General Electric Company made materially false and/or misleading statements and/or failed to disclose that: (1) PGE lacked effective internal controls over its energy trading practices; (2) PGE personnel had entered energy trades during 2020, with increasing volume accumulating late in the second quarter and into the third quarter, that created significant negative financial exposure for PGE; (3)as a result, the Company was reasonably likely to incur significant losses; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

FENC Lawsuit on behalf of: investors who purchased February 11, 2020 - August 10, 2020
Lead Plaintiff Deadline : November 2, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-information-request-form?prid=9397&wire=1

According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Odonate Therapeutics, Inc. (NASDAQ:ODT)

ODT Lawsuit on behalf of: investors who purchased December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline : November 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/odonate-therapeutics-inc-information-request-form?prid=9397&wire=1

According to the filed complaint, during the class period, Odonate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/606755/CLASS-ACTION-UPDATE-for-POR-FENC-and-ODT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders